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Immunolocalization of NAD-dependent 1113-hydroxysteroid dehydroge-
nase in human kidney and colon. The inactivation of physiological
glucocorticoids by 113-hydroxysteroid dehydrogenase (1113-HSD) confers
mineralocorticoid specificity to certain aldosterone target tissues. Both
NADP, and NAD-dependent isoforms of I 1f3-HSD have been described.
An NAD-dependent isoform of 11f3-HSD (llp-HSD2) was recently
cloned from human kidney. The present studies were designed to examine
the cellular distribution of I 1I3-HSD2 in human kidney and colon, and to
determine if the cellular distribution of 113-HSD2 within the human
kidney and colon is consistent with a role in conferring mineralocorticoid
specificity. Using antibodies against a fusion protein containing a portion
of the human llp-HSD2, immunohistochemical staining of human kidney
showed intense, specific staining of connecting tubules and cortical and
medullary collecting tubules and less intense staining in the cortical thick
ascending limb. No immunoreactivity was found in proximal tubules,
glomeruli, or blood vessels. Within the collecting tubules staining was
heterogeneous. The majority of cells showed intense cytoplasmic staining
while n-intercalated cells displayed much less immunoreactivity. Within
the colon, 11/3-HSD2 immunoreactivity was found predominantly in
surface epithelial cells but not in submucosal tissues. Thus, the distribution
of the cloned NAD-dependent 1113-HSD2 parallels the distribution of
mineralocorticoid receptors within the kidney and colon. These results
support the view that the NAD-dependent isoform of llp-HSD (11/3-
HSD2) provides mineralocorticoid specificity by inactivating glucocorti-
coids in an autocrine fashion.
The present studies were designed to examine the cellular
distribution of the recently identified enzyme, NAD-dependent
11/3-hydroxysteroid dehydrogenase, in human kidney and colon.
Aldosterone is one of the principal physiologic regulators of salt
transport by certain epithelia including the distal nephron, colon,
salivary glands, and sweat glands [1]. The cellular effects of
aldosterone in these target tissues are initiated by the binding of
aldosterone to intracellular Type I mineralocorticoid receptors,
which then initiates genomic events [1, 2]. However, since Type I
receptors have equal affinity for aldosterone, cortisol, and corti-
costerone [3], aldosterone target tissues must possess additional
mechanisms to account for the selective effects of aldosterone in
the face of a large excess of glucocorticoids. One such mechanism
is the oxidative inactivation of cortisol and corticosterone by
1 13-hydroxysteroid dehydrogenase [4, 5].
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Two isoforms of 1 113-HSD have been identified which differ in
terms of their cofactor requirements and affinity for substrate: a
low affinity, NADP-dependent 11/3-HSD [6, 7] and a high affinity,
NAD-dependent 1113-HSD [8—10]. An NAD-dependent isoform
of 11J3-HSD, termed 11/3-HSD2, was recently cloned from the
human kidney [11]. mRNA for this isoform was found in kidney,
colon, [11], and parotid gland (W.B. Reeves, unpublished results).
Based on this distribution, the 11 13-HSD2 isoform is an attractive
candidate for the 11f3-HSD which confers mineralocorticoid
specificity to epithelial target tissues. According to this view, the
1 1f3-HSD2 isoform should be present in the aldosterone-sensitive
cells of these target tissues such as the collecting duct and colonic
epithelial cell. Most previous attempts to localize the distribution
of 11f3-HSD within the kidney have used either antibodies against
the NADP-dependent llp-HSD (11/3-HSD1) isoform [12, 13], or
enzyme assays which did not distinguish between NAD and
NADP-dependent activity [14, 15]. It was pertinent, then, to
determine if the cellular distribution of 1 1/3-HSD2 within the
human kidney and colon, the two principal aldosterone target
tissues, is consistent with the current paradigm for its role in
conferring mineralocorticoid specificity. Therefore, we raised
antibodies against a fusion protein containing a portion of the
human 1113-HSD2 [111 and examined the distribution of the
11p-HSD2 protein in human kidney and colon by immunohisto-
chemistry.
Methods
Production of 1113-HSD2 fusion protein
A 399 bp fragment of the 1 1f3-HSD2 cDNA was amplified by
reverse transcription PCR (RT-PCR) of RNA from T84 cells, a
human colonic adenocarcinoma cell line which contains NAD-
dependent 11f3-HSD enzymatic activity [10]. The PCR primers,
selected from the sequence of the human 11J3-HSD2 [11], were:
forward, 5' CTG CIT CAA GAC AGA GTC 3' (897-914); and
reverse, 5' GCT CAG GYF TOG GTC CTG 3' (1279-1296).
RT-PCR was performed using the GeneAmp PCR reagents
(Perkin Elmer Cetus, Norwalk, CT, USA). One microgram of
total RNA was transcribed in a 20 p.l reaction volume by 50 U of
Molony Murine Leukemia Virus reverse transcriptase and 1 p.M of
the reverse primer at 42°C for 30 minutes. A control reaction was
run in the absence of reverse transcriptase. PCR amplification of
the resulting cDNA was performed in a total volume of 100 p.1.
The PCR mixture was subjected to 35 cycles of: 94°C for 30
seconds, 55°C for 30 seconds, 72°C for one minute, followed by a
271
272 Kyossev et a1s Immunolocalization of NAD-dependent 1113-HSD
10 minutes final extension at 72°C. Agarose gel electrophoresis of
the product revealed that a single band of the appropriate size
(399 bp) was obtained in the presence, but not absence, of reverse
transcriptase. The PCR product was ligated into the pGEM-T
vector (Promega, Madison, WI, USA) and then sequenced (Prism
DyeDeoxy Terminator sequencing kit, Applied Biosystems, Inc.)
to confirm that the plasmid insert was identical to the published
human 1113-HSD2 sequence.
A plasmid for the expression of a portion of the 1113-HSD2
protein as a fusion protein was constructed by excision of the
11/3-HSD2 fragment from the pGEM-T plasmid with NcoI and
NotI and then ligation of the fragment into the same restriction
sites of the pET-30a(+) vector (Novagen, Inc., Madison, WI,
USA). The resulting plasmid encoded amino acids 264 through
396 of the human 11/3-HSD2 as a fusion protein containing a
polyhistidine region to aid in the purification of the expressed
protein. NovaBlue competent cells (Novagen) were transformed
with the ligation mixture and plated on LB plates containing 30
jig!ml kanamycin. Plasmid DNA from one of the resulting colo-
nies was sequenced in both directions to confirm the proper
in-frame ligation of the insert. This plasmid DNA was then
transformed into the expression host BL21(DE3). A 500 ml
culture of the bacteria was induced to express the fusion protein
with 0.4 ms isopropyl /3-D-thiogalactopyranoside for 90 minutes
and harvested for purification of the fusion protein. The fusion
protein was purified to near homogeneity from the bacterial
inclusion bodies using a metal chelation column (HisBind resin,
Novogen) according to the manufacturer's recommendations.
Polyclonal antibody production
Rabbits were injected subcutaneously with 100 jg of purified
fusion protein emulsified in Freund's complete adjuvant. Rabbits
received booster injections of fusion protein (100 jig) in incom-
plete adjuvant after four and eight weeks. Immune serum was
obtained two weeks after the second boost.
Immunoblots
Microsomal proteins from an autopsy specimen of human
kidney were separated by 10% SDS polyacrylamide gel electro-
phoresis and transferred to a nitrocellulose membrane. The
membrane was blocked overnight in TBS (150 mi NaCI, 10 mM
Tris-HC1, pH 8.5) containing 5% non-fat dry milk. Strips of the
membrane were incubated with dilutions of sera in TBST (TBS
with 0.1% Tween 20) for one hour, washed in TBST, and then
incubated with a 1:2000 dilution of horseradish peroxidase-
coupled anti-rabbit Ig (Amersham Life Sciences, Buckingham-
shire, UK) for one hour. Antibody-labeled proteins were detected
by incubating the strips in a 1:1 dilution of ECL chemilumines-
cence reagents (Amersham) in water for 60 seconds followed by a
15 seconds exposure to autoradiography film (Hyperfilm, Amer-
sham).
Immunohistochemistiy
Seven separate specimens of human kidney were obtained
either at surgery for the removal of renal tumors (3 patients) or
for the repair of a stenotic renal artery (1 patient), or by
percutaneous renal biopsy during the evaluation of proteinuria or
possible transplant rejection (3 patients). Tissue from the sigmoid
colon and ascending colon was obtained from two patients
undergoing surgery for the removal of colon carcinomas. All of
the specimens had minimal or no histologic changes under light
microscopy. Formalin fixed, paraffin-embedded specimens were
cut into 5 jim Sections. The sections were deparaffinized using
xylene and a decreasing gradient wash of ethanol. Endogenous
peroxidase activity was blocked by incubating the sections for 30
minutes in methanol containing 0.3% H202. Immunohistochem-
istry was performed using the avidin/biotin complex method [16j
with reagents purchased from Pierce (ImmunoPure Peroxidase
ABC Staining kit) following the manufacturer's protocol. For
double staining against both 11f3-HSD2 and either Tamm-Hors-
fall protein or band 3 protein, slides were processed for 11J3-
HSD2 immunoreactivity and then were incubated with a 1:100
dilution of antibody to the Tamm-Horsfall protein (Organon
Teknika Corp.) or a monoclonal antibody to the human band 3
protein (kindly provided by Dr. Michael Jennings, University of
Arkansas for Medical Sciences). These second antibodies were
detected by a 30 minutes incubation with either an FITC-
conjugated anti-goat IgG (for Tamm-Horsfall antibody) or an
FITC-conjugated anti-mouse IgG (for the band 3 antibody).
Peanut agglutinin binding was determined by incubating kidney
sections which had already been stained for 1113-HSD2 with a
1:500 dilution of FITC-labeled peanut agglutinin (Biomeda Corp.,
Foster City, CA, USA) for 30 minutes. Following washes in PBS,
all fluorescently labeled slides were coverslipped with Gel/Mount
aqueous mounting media (Biomeda Corp.) and stored in the dark.
Slides were examined using an Olympus BH-2 microscope with an
epifluorescence attachment and photographed using an Olympus
PM-lOAD photomicrographic system.
Results
Following immunization, ELISA assays indicated that the rab-
bits developed a high titer (> 1:80,000) of antibodies against the
11/3-HSD2 fusion protein (data not shown). The specificity of the
immune serum is demonstrated by the Western blot in Figure 1.
Compared to the preimmune serum, the immune serum (1:10,000
dilution) detected a single protein with a molecular mass of
approximately 45 kDa. This molecular mass compares closely to
the predicted mass of the cloned IIf3HSD2, 44.1 kDa [11]. Lanes
3 and 4 in Figure 1 show that the reactivity against the 45 kDa
protein was blocked by competition with 10 and 100 ng/ml,
respectively, of free fusion protein. Thus, the immune serum
recognized a protein of the expected size for the llp-HSD2
protein and the immunodetection could be inhibited by the
11/3-HSD2 fusion protein. A protein of approximately 60 kDa was
recognized by both preimmune and immune sera. The reactivity
to this protein was not inhibited by the fusion protein.
The results of immunolocalization studies of the 1113-HSD2
protein within the human kidney cortex using the 1113-HSD2
antiserum are shown in Figures 2 to 5. Figure 2A shows that using
the immune serum, striking immunoreactivity was detected over
clusters of distal tubules. Specimens from all seven individuals
showed the same pattern of immunoreactivity. In contrast, the
preimmune serum (1:500 dilution) produced no detectable stain-
ing (Fig. 2B). In addition, staining of these tubule segments with
the immune serum was abolished by preincubation of the immune
serum with excess fusion protein (not shown). Under higher
magnification (Fig. 2C), it is clear that the staining of distal tubule
cells was cytoplasmic with no nuclear staining. It is also apparent
that there was both intra- and inter-tubule variability in the
intensity of staining. Some tubules (Fig. 2C, open arrow), for
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Fig. 1. Western blot analysis of human kidney microsomes using 11p-HSD2
antiserum. One hundred micrograms of human kidney microsomes were
loaded into a 4 cm wide well of a 10% polyacrylamide gel, separated by
electrophoresis, and transferred to a nitrocellulose filter. Strips of the filter
were incubated with either a 1:5000 dilution of pre-immune serum (lane 1)
or a 1:10,000 dilution of immune serum (lanes 2 to 4). In lanes 3 and 4, the
antibody incubation was performed in the presence of either 10 (lane 3) or
100 nglml (lane 4) of fusion protein. The positions of molecular weight
markers are shown on the left.
example, stained fairly lightly. In addition, within the more heavily
staining segments, there was a population of cells which exhibited
little or no immunoreactivity (Fig. 2C, solid arrow). Within the
medulla, 1113-HSD2 immunoreactivity was found in outer medul-
lary collecting ducts (Fig. 2D) and also in the initial portion of the
inner medullary collecting duct (IMCD). Staining of the outer
medullary collecting ducts was less intense, and more uniform,
than in cortical collecting ducts. Immunostaining of the IMCD
decreased abruptly midway through the inner medulla such that
the terminal IMCD and papillary surface epithelium were nega-
tive for 11f3-FISD2 immunoreactivity.
Blood vessels ranging in size from segmental renal arteries to
afferent and efferent arterioles were examined in seven separate
kidney specimens. None of the blood vessels demonstrated 11/3-
HSD2 immunoreactivity. Figure 3A shows an interlobar artery
adjacent to a collecting duct. No staining was evident in either the
endothelium or smooth muscle layer of the vessel while cells in an
adjacent collecting duct showed intense immunoreactivity. Figure
3B shows that no staining was seen over glomeruli or proximal
tubules.
Double-staining studies were performed to identify the sites of
11/3-HSD2 immunoreactivity in the renal cortex. Figure 4 shows a
field stained for both 11/3-HSD2 (Fig. 4A) and for Tamm-Horsfall
protein, a marker for the thick ascending limb of Henle (Fig. 4B).
The open arrows in Figure 4 show that those segments which had
apical Tamm-Horsfall staining also had relatively faint, but defi-
nite, 11f3-HSD2 staining. In contrast, the intensely stained 1113-
HSD2 segments (solid arrows) were negative for Tamm-Horsfall
protein. Likewise, the lightly staining tubule in Figure 2C, indi-
cated by the open arrow, was shown to be a thick ascending limb
by double-staining. These results are consistent with low levels of
1113-HSD2 expression in the cortical thick ascending limb of
Henle. Tissue sections were also stained with both 11f3-HSD2
antibodies and a monoclonal antibody against the human band 3
protein. The latter antibody stains the basolateral membrane of
a-intercalated cells in connecting tubules and collecting ducts [17,
181. Figure 5 A and B show that the tubule segments which stained
heavily for 11f3-HSD2 were connecting tubules and cortical
collecting ducts as indicated by the scattered basolateral band 3
immunoreactivity. Moreover, within these segments, the cells
which labeled with the band 3 antibody, the a-intercalated cells,
had less 11/3-HSD2 immunoreactivity than their neighboring cells.
These results are consistent with the view that high levels of
11/3-HSD2 protein are expressed in connecting tubules and
cortical collecting ducts and that expression is high in principal
cells relative to a-intercalated cells. We also stained kidney
sections with both 11/3-HSD2 antiserum and peanut agglutinin
(Fig. 5 C, D). In the rabbit kidney, peanut agglutinin binds to the
apical membrane of J3-intercalated cells [17]. In other species,
however, peanut agglutinin reactivity is not restricted to 13-inter-
calated cells [19, 201. Our results show that peanut agglutinin
labeled the apical surfaces of most collecting duct cells (Fig. 5D),
and that these cells also had high levels of 11/3-HSD2 immuno-
reactivity (Fig. 5C). In contrast, peanut agglutinin did not label
the majority of the lightly staining cells of the cortical collecting
duct (arrows in Fig. 5 C, D) which we have identified as
a-intercalated cells (see above).
Staining of human colon with the 11/3-HSD2 antiserum yielded
immunoreactivity in the surface epithelial cells (Fig. 6). The
intensity of staining decreased at progressively deeper levels
within the epithelial crypts. No immunoreactivity was seen in
submucosal blood vessels or visceral smooth muscle (not shown).
Discussion
An important mechanism for conferring mineralocorticoid se-
lectivity to otherwise nonselective receptors is the oxidative
inactivation of glucocorticoids by the enzyme 11 /3-hydroxysteroid
dehydrogenase [41. In the kidney, for example, inhibition of
11p-HSD abolishes the selectivity of mineralocorticoid receptors
for aldosterone [4, 21], and results in salt retention and hyperten-
sion consequent to the activation of both mineralocorticoid and
glucocorticoid receptors by the high ambient glucocorticoid levels
[21—23]. 11/3-HSD was originally characterized, purified, and
cloned from the liver [6, 7]. The liver isoform (11/3-HSD1) is
NADP-dependent and has a low affinity for cortisol. Immunolo-
calization studies using antibodies against the 11 f3-HSD1 isoform
revealed immunoreactivity primarily in the proximal tubule [12,
13]. This localization is inconsistent with a role for this isoform in
regulating hormone receptor selectivity in the mineralocorticoid-
responsive distal tubule. NAD-dependent I 113-HSD enzymatic
activity was subsequently described in renal collecting duct cells
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Fig. 2. Immunohistochemical localization of 11J3-HSD2 in human kidney. (A) A section of kidney cortex incubated with a 1:1000 dilution of the immune
serum showing immunoreactivity over a discrete population of tubules. (B) An adjacent section incubated with a 1:500 dilution of preimmune serum
showing the lack of immunoreactivity. Both A and B were lightly counterstained with methyl green following the peroxidase detection step (X60). (C)
A section of cortex showing the heterogeneous pattern of 1 113-HSD2 immunoreactivity. The darkly staining tubules are collecting ducts. The solid arrow
points to a collecting duct cell with relatively little immunoreactivity. The open arrow points to a tubule segment with light, homogeneous
immunostaining. Double-staining of this Section for the Tamm-Horsfall protein demonstrated that this tubule segment is a cortical thick ascending limb
(X600). (D) A section of renal medulla showing 11/3-HSD2 immunoreactivity over rnedullary collecting ducts (X300).
and in colonic epithelial cells [8—10]. Based on this tissue distri-
bution, it has been proposed that the NAD-dependent isoform
endows mineralocorticoid selectivity to epithelial target tissues [8,
24]. An NAD-dependent isoform, 11/3-HSD2, was recently cloned
by Albiston et al [11]. In the present study, we raised antibodies
against the 1 1f3-HSD2 enzyme and performed immunohistochem-
ical studies on human kidney and colon to determine if this
enzyme is, in fact, expressed in mineralocorticoid responsive
target cells.
We first established that the antisera recognized specifically the
1113-HSD2 protein. The Western blot studies (Fig. 1) indicate
that, aside from a band at about 60 kDa which was also recognized
by preimmune serum, the immune sera recognized a single 45
kDa protein in human kidney microsomes. The predicted size of
the 11/3-HSD2 protein is 44.1 kDa [11]. In addition, the reactivity
of immune serum with the 45 kDa protein (but not the 60 kDa
protein) could be inhibited by the addition of excess 1113-HSD2
fusion protein. A 45 kDa protein was also detected (data not
shown) in microsomes from T84 cells, a colonic cell line which
expresses 1113-HSD2 enzyme activity [10]. The identity of the 60
kDa protein which was recognized by both preimmune and
immune sera is not known. However, since no immunoreactivity
was seen on immunohistochemical studies using the preimmune
serum (Fig. 2B), and since immunoreactivity on immunohisto-
chemistry could be inhibited by free fusion protein, the labeling
seen with the immune serum must represent the 45 kDa 1 113-
HSD2 protein.
Immunohistochemical studies of human kidney cortex showed
staining of a discrete population of tubules having a morphology
and distribution consistent with the connecting tubule and cortical
collecting duct. In contrast, proximal tubules, which contain
11p-HSD1 [12, 13], did not stain for 11f3-HSD2. Likewise, no
staining was seen in renal blood vessels or in glomeruli in any of
the specimens examined. The exact sites of expression of 1 1/3-
HSD2 were defined in double-labeling studies. First, Tamm-
Horsfall protein antibodies were used to identify cortical thick
ascending limb segments. These segments did display 1 1f3-HSD2
reactivity, although at clearly lower levels than in the collecting
duct (Figs. 2C and 4). Measurements of 11f3-HSD enzyme activity
in isolated nephron segments showed that the cortical thick
ascending limb from rabbit and rat had relatively high levels of
11/3-HSD, comparable to the levels seen in the collecting duct [14,
15]. In the mouse kidney, however, 1113-HSD activity in the
cortical thick ascending limb was considerable lower than in the
collecting duct [15]. Those studies did not differentiate between
11p-HSD1 and 11f3-HSD2. The current results indicate that, in
human kidney, the cortical thick ascending limb expresses the
11J3-HSD2 isoform at low levels relative to the collecting duct.
While the physiologic role of mineralocorticoids in the thick
ascending limb of Henle is uncertain, mineralocorticoid receptors
are present in the cortical and medullary portions of the thick
ascending limb [25, 26] and, under certain circumstances, miner-
alocorticoids have been shown to influence sodium chloride
transport by the thick ascending limb [27—30]. Thus, the presence
of 11f3-HSD2 in the thick ascending limb is consistent with its
proposed role in controlling the access of steroid hormones to the
mineralocorticoid receptor. Whorwood et al [31] performed in
situ hybridization of human kidney using an 1113-HSD2 antisense
probe and detected no hybridization over the loop of Henle. It is
likely that their technique lacked sufficient sensitivity to detect the
lower levels of 1 1/3-HSD2 message present in the thick ascending
limb.
The primary site for mineralocorticoid action in the kidney is
the collecting duct, particularly the principal cell, where miner-
alocorticoids increase the rates of sodium absorption and potas-
sium secretion [1]. Previous studies of isolated collecting duct
segments from rabbit, rat and mouse [14, 15], and of immunodis-
sected rabbit collecting duct cells [32] demonstrated high levels of
1113-HSD enzyme activity in this segment. In addition, Naray-
Fejes-Toth and Fejes-Toth [33] recently reported the cloning of
an NAD-dependent 1113-HSD from rabbit collecting duct cells
which shares 85% homology to the human 11/3-HSD2. Likewise,
11J3-HSD2 mRNA was detected in the collecting duct of human
kidney by in situ hybridization [31], although the intracellular and
intercellular distribution could not be determined from that study.
Our studies clearly show that high levels of 11/3-HSD2 protein are
expressed in the human connecting duct, cortical collecting duct
and medullary collecting duct. Moreover, we determined that
there is cellular heterogeneity of 11/3-HSD2 expression within the
collecting duct. Specifically, principal cells stained intensely for
1113-HSD2 protein. This is consistent with the demonstration of
high levels of both mineralocorticoid receptor and 1 1/3-HSD
enzyme activity in principal cells [32]. In addition, we found that
cs-intercalated cells, characterized by basolateral staining for the
band 3 anion exchange protein (Fig. 5), had little I 1/3-HSD2
enzyme when compared to principal cells. Neither the level of
1 113-HSD enzyme activity nor the number of mineralocorticoid
receptors in a-intercalated cells have been reported. 13-interca-
lated cells represent a significant proportion (> 50%) of the
intercalated cell population in the cortical collecting ducts from
rabbit and rat [17, 18, 34]. Although we did not stain specifically
for 13-intercalated cells, we observed that virtually all peanut lectin
positive cells, which includes both principal cells and /3-interca-
lated cells, stained heavily for 11/3-HSD2. Accordingly, either
/3-intercalated cells represent only a minor fraction of the inter-
calated cell population in the human collecting duct or, more
likely, /3-intercalated cells have similar amounts of 11 /3-HSD2 as
principal cells and significantly higher amounts of I 1/3-HSD2 than
cs-intercalated cells. In contrast, a study of immunodissected
rabbit cortical collecting duct cells found that 13-intercalated cells
contained only about one-tenth the activity of 1113-HSD2 as
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Fig. 3. Sections incubated with a 1:1000 dilution of]] f3-HSD2 antiserum showing the absence of staining over renal blood vessels (A), proximal tubules or
glomeruli (B). For comparison, each field also contains a darkly stained collecting duct (X300).
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Fig. 4. Co-localization of 113-HSD2 and Tamm-Horsfall protein. A section of kidney cortex was stained for both 1 113-HSD2 and Tamm-Horsfall protein
(see Methods). (A) Light microscopy showing the distribution of 1113-HSD2 immunoreactivity. (B) Fluorescence microscopy showing the distribution
of Tamm-Horsfall protein. The open arrows point to cortical thick ascending limb segments while the closed arrows indicate collecting ducts (X300).
principal cells [32]. Our finding that a-intercalated cells appar-
ently express much less 11p-HSD2 protein than f3-intercalated
cells is also at variance with an RT-PCR analysis of rabbit a and
13-intercalated cells, which showed that message levels for 11j3-
HSD2 were similar in the two cell types [33]. This difference could
be due to a difference in species or methodologic problems in
quantitating either protein or message levels by immunohisto-
chemistry or RT-PCR, respectively. The finding of detectable
amounts of 11p-HSD2 immunoreactivity in both a and particu-
larly 13-intercalated cells suggests that these cells may be targets of
mineralocorticoid action. In this regard, 13-intercalated cells have
been shown to contain mineralocorticoid receptors [32]. However,
there are no clear data, as yet, demonstrating direct effects of
mineralocorticoids on intercalated cell function.
The distal colon is a second major site of mineralocorticoid
action [351. Our studies indicate that 11j3-HSD2 is present in
colonic epithelial cells and that the level of expression is greater in
surface cells than in crypt cells. NAD-dependent 1113-HSD en-
zyme activity has been demonstrated in rat and human colon [24,
36] and in cultured human colonic epithelial cells [10]. Moreover,
both the activity of NAD-dependent 11p-HSD [24] and the
number of mineralocorticoid receptors [371 is greater in surface
cells of the colon than in crypt cells. Thus, the distribution of the
11f3-HSD2 protein in the colonic epithelium determined by
immunostaining parallels the distribution of NAD-dependent
1 1f3-HSD activity and mineralocorticoid receptors.
After these studies were completed, Krozowski et al [381
reported the immunolocalization of 11 13-HSD2 in human kidney
using an antipeptide antibody. However, they did not determine
the sites of expression using segment specific markers and did not
address the issue of cellular heterogeneity of 11f3-HSD2 expres-
sion within the collecting duct. In the present study, we firmly
established the thick ascending limb, connecting tubule and
collecting duct as the sites of 11/3-HSD2 expression, and clearly
demonstrated heterogeneity of 1 1/3-HSD2 within the connecting
tubule and collecting duct. Finally, in addition to its presence in
the distal tubule, Krozowski et al also reported immunostaining in
vascular smooth muscle cells and in glomerular epithelial cells
[38]. In contrast, as shown in Figure 3 A and B, we found no
evidence of glomerular or vascular staining in any of the tissue
specimens we examined. We note, in this regard, that our results
are consistent with studies which demonstrated NADP-depen-
dent, rather than NAD-dependent 1113-HSD enzyme activity in
vascular smooth muscle cells [36, 391.
In summary, we found abundant staining for I 1p-HSD2 protein
in the connecting tubules and cortical collecting ducts, and lesser
amounts of staining in the cortical thick ascending limb. Within
the collecting duct, staining was predominantly in principal cells
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Fig. 5. Co-localization of 11f3-HSD2 and band 3 protein (A and B) and peanut agglutinin (C and D). (A) Light microscopy showing the distribution of
1 113-HSD2 immunoreactivity. (B) Fluorescence microscopy of the same field as in A showing the distribution of band 3 protein. Arrows in A and B point
to cells with basolateral band 3 staining (x300). (C) Light microscopy showing the distribution of I lp-HSD2 immunoreactivity. (D) Fluorescence
microscopy of the field in C showing the apical staining of collecting and connecting duct cells with peanut agglutinin. Arrows in C and D point to cells
with faint 113-HSD2 immunoreactivity which also lacked apical peanut agglutinin staining (x300).
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Fig. 6. Localization of 1113-HSD2 in human colon. (A) Section from the sigmoid colon incubated with a 1:500 dilution of 1113-HSD2 antiserum showing
immunoreactivity in the surface epithelial cells. (B) An adjacent section incubated with 1:500 dilution of pre-immune serum. Both sections were
counterstained with methyl green (X 150).
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and -interca1ated cells while a-intercalated cells had little immu-
noreactivity. In the colon, 11/3-HSD2 was located in surface
epithelial cells. Thus, the pattern of 11/3-HSD2 distribution
matches the distribution of mineralocorticoid receptors and mm-
eralocorticoid actions in both the kidney and colon [25, 26, 371.
These data, along with recent identification of mutations in the
11f3-HSD2 gene in patients with the syndrome of apparent
mineralocorticoid excess [40, 41], provide strong support for the
conclusion that the 1 1j3-HSD2 enzyme confers mineralocorticoid
specificity to aldosterone target cells in an autocrine fashion.
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